Engflag

Berirab -P

Quick links to important sections

Berirab -P

Berirab -P_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Berirab -P

Quick Facts

Property Description
Active ingredient Human Rabies Immunoglobulin (HRIG)
Form Solution for injection
Pharmacological class Immunoglobulins and Immune Sera (Passive Immunizing Agent)
Common use Rabies Post-Exposure Prophylaxis (PEP)
Origin Biologic derivative (Human Plasma)

What Type of Medicine is Berirab -P?

Berirab -P is precisely identified as Human Rabies Immunoglobulin (HRIG), an established and critical biological preparation classified within the high-level pharmacological class of Immunoglobulins and immune sera. As a passive immunizing agent, its function is to supply immediate, pre-formed virus-neutralizing antibodies directly to the body, a key differentiation from an active immunizing agent like a vaccine. This specific product is often associated with the manufacturer CSL Behring GmbH and is supplied as a sterile solution for injection, distinguishing it as a readily available, specific-source form of HRIG in the medical supply chain.

Understanding the Composition and Purpose of Berirab -P

The active ingredient comprises highly purified Immunoglobulin (primarily IgG) containing concentrated levels of antibodies against the Rabies Virus. As a biologic derivative of human plasma, this homologous origin is clinically recognized for providing a favorable safety profile compared to heterologous immunoglobulin sources. Berirab -P is a single product used to provide indispensable rapid defense in rabies post-exposure prophylaxis (PEP). Its general purpose is to ensure the virus is neutralized at the site of potential entry, a method that is critical for stopping viral progression until the concurrently administered rabies vaccine can stimulate the body's own defense.

Regulatory References

  1. WHO Position Paper on Rabies

What side effects are possible with Berirab -P?

The safety profile for Human Rabies Immunoglobulin (Berirab-P) details officially documented adverse reactions classified by frequency and body system according to regulatory standards (e.g., FDA Prescribing Information and SmPC).

Adverse Reactions Classified by System

Adverse reactions most frequently reported in clinical studies fall into the category of General disorders and administration site conditions, including local pain, swelling, tenderness, and stiffness at the injection site. Generalized reactions are also considered common and may involve Nervous system disorders such as headache and dizziness, and Musculoskeletal disorders like muscle pain (myalgia) and joint pain (arthralgia). Less common effects documented include fever, chills, malaise, and reactions in the Gastrointestinal system (nausea, vomiting).

Serious Safety Considerations

The most clinically significant adverse reactions are related to the Immune system disorders. Regulatory documents note the rare but serious risk of anaphylactic shock or severe hypersensitivity, which can occur even in patients previously treated with immunoglobulin. Due to its origin from pooled human plasma, there is a theoretical, label-mandated risk of transmitting infectious agents (e.g., certain viruses, CJD agent), although the plasma is tested and treated to minimize this concern. Other serious risks noted in safety warnings for immunoglobulin products include thrombotic events (blood clots) and hemolysis (red blood cell breakdown).

Population-Specific Cautions and Limitations

Specific cautions are documented for individuals with Immunoglobulin A (IgA) deficiency, as they are at a higher risk of developing severe allergic reactions to human immunoglobulin products containing IgA. Caution is also specified for patients with cardiovascular risk factors, known blood clotting problems, or those experiencing prolonged immobility, due to the risk of thrombosis. A key regulatory restriction is that Human Rabies Immunoglobulin may impair the efficacy of concurrently or subsequently administered live attenuated virus vaccines (e.g., measles, rubella) for a period of up to three to four months.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that the consequences of an overdose are not known, as a specific toxicological profile for Human Rabies Immunoglobulin (Berirab -P) is not defined. The primary documented risk of administering a dose exceeding the recommended amount is the potential for interference with the development of active immunity from the concurrently administered rabies vaccine, which may compromise the overall treatment effectiveness.

Documented Risks and Emergency Actions

An overdose scenario is primarily associated with the risk of anaphylactic shock and other severe systemic reactions, which are exaggerations of known adverse effects. Severe cardiovascular reactions may occur, particularly if the product is inadvertently injected into a blood vessel (intravascularly).

Official labeling mandates that urgent medical attention is needed immediately if a true allergic or anaphylactic type reaction occurs. In such a scenario, the injection must be immediately discontinued. Healthcare providers are officially instructed to have epinephrine available for the treatment of acute allergic symptoms.

Management of an overdose relies on symptomatic and supportive treatment. Furthermore, patient monitoring is required for an extended period, especially following an inadvertent intravenous injection, to observe for potential severe outcomes.

Therapeutic Uses of Berirab -P

Berirab -P is commonly used to address the risk associated with a serious viral condition following documented or suspected exposure to the Rabies Virus. The administration of Human Rabies Immunoglobulin (HRIG) is considered an important component of the post-exposure prophylaxis regimen for previously unvaccinated individuals. The medicine provides passive immune support that supports the localized addressing of the viral threat until the active immunity response develops.

This medication is relevant in conditions characterized by periods of heightened symptoms or risk, specifically in high-risk clinical situations like Category III exposures, deep transdermal bites, and mucous membrane contamination. The main therapeutic benefit involves providing prophylactic support during the crucial incubation period, contributing to supporting defense against the onset of symptoms of rabies.

“This treatment is used to provide supportive defense when a high-risk exposure has occurred.”

This targeted, supportive intervention is applied when prompt supportive care is needed, assisting with local defense against the virus. Indications for use are primarily related to post-bite management, contamination management, and undocumented exposure scenarios.

Quick Fact: Support for Viral Risk
Therapeutic Benefit Provides passive immune support to address the viral threat.
Focus Scenario High-risk, Category III exposures in unvaccinated individuals.
Symptom Management Contributes to supporting defense against the onset of significant symptomatic burden.

Eligibility and Restrictions for Use

Who can and cannot use Berirab -P?

The eligibility rules for Berirab -P (Human Rabies Immunoglobulin, HRIG) are strictly defined by regulatory authorities based on two main criteria: prior immunization status and the timing relative to the rabies vaccine course. The medicine is indicated for use in all ages—including infants, children, and older adults—who have suffered a rabies exposure and are previously unvaccinated. Due to the life-threatening nature of rabies, no absolute contraindications are known when PEP is required.

Eligibility Status Population/Condition
Contraindicated Individuals with a confirmed, complete prior rabies vaccination.
Contraindicated Administration later than seven days after the first dose of the rabies vaccine.
Use with Caution Patients with isolated IgA deficiency (risk of hypersensitivity).
Use with Caution Patients with bleeding disorders or thrombocytopenia.
Permitted/Not Contraindicated All ages (pediatric and geriatric).
Permitted/Not Contraindicated Pregnant and lactating women.

Government documents emphasize that use is permitted across all life stages, even with certain comorbidities, provided the immediate need for life-saving post-exposure prophylaxis exists. The primary exclusions are time-based or related to a patient’s established immunity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Berirab -P (Human Rabies Immunoglobulin, HRIG) is defined by its function as a passive immunizing agent, primarily involving immunological interference with certain active immunizing medicines.

Interactions with Active Immunizing Agents

The administration of Berirab -P must adhere to strict regulatory guidelines concerning the Rabies Vaccine. Official documentation states that Berirab -P must never be administered in the same syringe or the same anatomical site as the first dose of the rabies vaccine component, as this is a fundamental restriction to avoid local antigen neutralization. Furthermore, HRIG is not indicated for administration more than seven days following the first dose of the rabies vaccine, a mandatory restriction tied to the expected onset of vaccine-induced active immunity.

Berirab -P may also cause immunological interference with subsequently administered live attenuated virus vaccines. To manage this, immunization with Measles vaccine must be deferred for 4 months, and immunization with other live attenuated virus vaccines (including Mumps and Rubella) must be deferred for 3 months following administration of this product.

Other Documented Interactions

The medicine may cause a transient rise of passively transferred antibodies, potentially leading to misleading positive results in certain serologic tests, such as the Antiglobulin Test (Coombs' test). Official regulatory sources currently do not document interactions involving metabolic enzymes (e.g., CYP), drug transporters, food, alcohol, or herbal products.

Mechanism of Action

Berirab -P is a preparation of Human Rabies Immunoglobulin (HRIG), a polyclonal antibody product. Its mechanism constitutes passive immunization. The molecular target is the Rabies virus (RABV). The product contains specific anti-rabies antibodies, primarily of the Immunoglobulin G (IgG) class, derived from the plasma of immunized human donors.

Following administration, the antibodies establish an immediate, exogenous supply within the peripheral tissues and systemic circulation. These IgG antibodies interact directly with and bind to the surface glycoproteins of the Rabies virus, specifically at the site of potential viral entry. This binding interaction results in neutralization of the viral particles, which blocks the virus from engaging with and subsequently entering host cells, particularly peripheral nerve endings. By neutralizing the viral inoculum at the site of inoculation, the molecular pathway of viral uptake and subsequent axonal retrograde transport towards the central nervous system is inhibited. This provides an acute, high-concentration local and systemic clearance of the virus, transiently modulating the biological environment until the host's own adaptive immune response can generate its own sufficient titer of endogenous neutralizing antibodies.

Dosage and Administration Information

Administration Protocol

Berirab -P (Human Rabies Immunoglobulin or HRIG) is provided as a solution for injection and is subject to precise guidelines for its administration during post-exposure prophylaxis. The medicine is strictly a single-dose, non-repeatable intervention.

The official dosing schedule is determined by the patient's actual body weight, calculated at 20 International Units (IU) per kilogram (kg). This specific dose must not be exceeded, as established guidelines indicate that excessive amounts may potentially interfere with the body’s active immune response to the concurrently administered rabies vaccine.

Procedural Administration

The administration procedure involves both local and systemic routes. The first priority is to administer as much of the calculated dose as anatomically feasible via wound infiltration directly into and around the exposure site. Any remaining volume not used for infiltration is subsequently administered via intramuscular (IM) injection at a separate location. In specific instances where IM injection is strictly contraindicated (e.g., patients with a known coagulation disorder), the remaining volume may be administered via the subcutaneous (SC) route.

A critical procedural instruction requires the immunoglobulin to be given concurrently with the first dose of the rabies vaccine, preferably on the same day (Day 0), and generally no later than seven days thereafter. Furthermore, the immunoglobulin and the vaccine must always be administered at contralateral sites (different limbs or body locations) and must not be mixed in the same syringe. These defined constraints apply uniformly to all age groups, as the dose is calculated based on weight regardless of whether the patient is an adult or a child.

Recent Clinical Evidence

Research evidence / Overview of studies for Berirab -P

Evidence for use in Rabies Post-Exposure Prophylaxis (PEP)

The established research framework for using this treatment is based on the clinical experience and research for the class of human rabies immunoglobulin products, used as a standard component of Rabies Post-Exposure Prophylaxis (PEP). Because of the serious nature of the disease, ethical constraints prevent conducting clinical trials that compare the treatment against a placebo in exposed patients. As a result, the evidence relies on long-standing field experience and observational studies that monitor outcomes in exposed populations. Research has explored the administration of this treatment to supply immediate, temporary antibodies at the site of exposure, a method consistent with global public health recommendations.

Evaluating Immunogenicity and Comparative Trials

Research has evaluated how products like Berirab -P compare to existing treatments through randomized, active-controlled non-inferiority studies. These trials focus on specific laboratory outcomes, such as measuring the level of Rabies Virus Neutralizing Antibodies (RVNA) in the blood at defined time intervals. The primary outcome monitored is the achievement of an antibody titer level of ge 0.5 IU/mL, a regulatory measurement used as a surrogate marker. Studies reported measurements indicating that the product's antibody levels were within a predefined range compared to the established comparator products. Reports from historical use of the combined immunoglobulin-plus-vaccine regimen describe patterns related to disease prevention when administered promptly.

Long-term Studies and Follow-up

Clinical and comparative trials for this immunoglobulin component typically focus on short-term follow-up, with primary outcomes measured around Day 14. Longer-term observation for patient survival and prevention of the disease is generally derived from large, long-term observational cohorts that track the outcomes of the complete PEP regimen. Studies have included pediatric patients, covering infants and children considered for PEP, with findings suggesting similar antibody patterns to those observed in adults. As the research focuses on the short-term function of the immunoglobulin to supply temporary immune support until the vaccine takes effect, the long-term patterns of the immunoglobulin component itself are not fully established.

Key Limitations and Research Gaps

The principal limitation in the research is the ethical constraint that prevents modern, direct, randomized, placebo-controlled trials for the immunoglobulin component itself. Therefore, evidence is based on surrogate endpoints (antibody titers) rather than direct observation of clinical prevention rates. Limited information is available from specific studies focused on certain high-risk groups or individuals with underlying chronic conditions. Research also explored the monitoring of potential interaction between the passively administered antibodies and the active immune response generated by the rabies vaccine.

Frequently Asked Questions (FAQ)

Common questions about Berirab -P (FAQ)

Q: Is Berirab -P the same as the standard rabies vaccine?

No, Berirab -P is classified as an Immunoglobulin, which is a type of passive immunizing agent. This means it supplies ready-made antibodies immediately. The standard rabies vaccine is an active immunizing agent that stimulates your body to produce its own long-term antibodies. They are distinct types of medicine that are typically used together.

Q: What is the difference between Berirab -P and other RIG products?

Berirab -P is a Human Rabies Immunoglobulin (HRIG) product. This indicates that the specific rabies antibodies it contains are derived from the plasma of immunized human donors. Other products in this class may sometimes be derived from animal sources, which is the key difference from the human-sourced product.

Q: Does Berirab -P interact with common pain relievers?

Official regulatory documents and product information primarily focus on interactions with other vaccines, which can involve interference with the immune system. They state that specific interactions with non-immunological agents, such as metabolic enzymes, food, alcohol, or common pain relievers, are not currently documented in the official label.

Q: What are the official warnings listed for Berirab -P?

Official warnings noted for human immunoglobulin products like this one highlight the rare but serious risk of severe allergic reactions (anaphylaxis). Additionally, due to its human plasma origin, there is a theoretical, label-mandated risk of transmitting infectious agents, and a warning for the potential for thrombotic events (blood clots) in certain vulnerable patients.

Q: What medications are known to interact with Berirab -P?

Berirab -P is known to interact with the concurrently administered Rabies Vaccine (requiring different injection sites). It may also impair the effectiveness of subsequently given live attenuated virus vaccines, specifically mentioning vaccines for Measles, Mumps, and Rubella. Official information recommends deferring these vaccines for several months.

Q: What kind of research has been done on Berirab -P?

Research involves studies that compare the product to other immunoglobulins by measuring the level of Rabies Virus Neutralizing Antibodies (RVNA) in the blood. Because of the serious nature of the disease, clinical prevention rates are generally derived from long-term observations of populations treated with the full post-exposure regimen, rather than direct comparison against a placebo.

Q: Is there a maximum time limit after exposure for Berirab -P to be given?

Official guidelines recommend that Berirab -P be given as soon as possible after exposure. It is typically not indicated for administration later than seven days after the first dose of the rabies vaccine has already been given, as the body's active immunity is expected to begin around that time.

Q: How quickly does Berirab -P start working after it's given?

As a passive immune agent, Berirab -P provides an immediate supply of pre-formed antibodies that begin neutralizing the virus at the wound site right after administration. This immediate action provides temporary immune support in post-exposure situations.

Q: Does Berirab -P contain live or inactive virus?

No. According to the official product information, Berirab -P is a solution containing purified antibodies (Immunoglobulin G) derived from human plasma. It is not a vaccine and does not contain any live, attenuated, or inactive rabies virus particles.

Q: Is it normal to feel tired after getting Berirab -P?

Adverse reaction data for this type of product includes reports of generalized reactions. The official documents list both fatigue and malaise (a general feeling of being unwell) as documented side effects.

Q: Does Berirab -P offer long-term protection?

No. The protection provided by the immunoglobulin is considered temporary and short-term (passive immunity), which is designed to bridge the gap until the rabies vaccine component takes effect and stimulates the body’s own long-term immune response.

Q: Is Berirab -P a prescription-only medicine?

Yes. As an injectable biological product intended for life-saving post-exposure prophylaxis, it is legally classified as a prescription-only medicine that must be ordered and administered by a qualified healthcare professional.

Q: Why do some people receive a larger dose of Berirab -P than others?

The total dose of Berirab -P a person receives is standardized to be proportional to their size. The total dose is precisely calculated based on the patient's actual body weight. This is why the total amount administered varies between individuals.

Q: What is the active component of Berirab -P?

The single active component is Human Rabies Immunoglobulin (HRIG). This component is composed of highly purified Immunoglobulin G (IgG) antibodies, which are the specific proteins responsible for neutralizing the rabies virus.

Q: Does Berirab -P affect blood tests or lab results?

Yes, it may. The antibodies passively transferred into the blood can cause a transient rise in certain antibody levels. Official documents note this may lead to misleading positive results in specific serologic tests, such as the Antiglobulin Test (Coombs' test).

Q: What is the general success rate described for Berirab -P when used as directed?

The use of Human Rabies Immunoglobulin as part of the complete Post-Exposure Prophylaxis (PEP) regimen is considered highly effective by major public health bodies. When the full protocol—including wound care, immunoglobulin, and vaccine—is administered correctly and promptly, official sources describe the prevention of rabies as a highly reliable intervention.

Q: Are there different brand names for the same type of medicine as Berirab -P?

Yes. Berirab -P is a brand name for a type of medicine known as Human Rabies Immunoglobulin (HRIG). There are other brand names for this product class available globally, all containing the same main active ingredient.

Q: How does Berirab -P differ from a tetanus shot?

Berirab -P provides specific antibodies directed only against the Rabies virus. A tetanus shot is a separate medical product—either a vaccine or an immune globulin—that provides protection specifically against the Tetanus toxin.

Q: Are there guidelines for giving Berirab -P in tropical countries?

Yes. The administration guidelines, including the specific dose calculation and the requirement for co-administration with a vaccine, are consistent worldwide. These protocols are standardized and set by international health organizations such as the World Health Organization (WHO) for use globally.

Q: What is the manufacturing process of Berirab -P like?

Berirab -P is a biologic derivative manufactured from the pooled plasma of human donors who have been immunized against rabies. The manufacturing process involves purification, fractionation, and several steps to inactivate potential viruses, such as pasteurization, to ensure product safety.

Q: Is the use of Berirab -P recommended by international health organizations?

Yes, the use of Human Rabies Immunoglobulin is strongly recommended by key international health bodies, including the World Health Organization (WHO), as an essential, life-saving component of the full Post-Exposure Prophylaxis (PEP) regimen.

Q: Does Berirab -P contain preservatives or additives?

Official composition information confirms that the solution for injection contains the active immunoglobulin along with excipients. These additives typically include stabilizers and salts like aminoacetic acid and sodium chloride to maintain the product's stability and pH.

How should Berirab -P be stored and disposed of?

How to Store and Dispose of Berirab P

Berirab P (Human Rabies Immunoglobulin) must be stored according to specific regulatory requirements to maintain its stability.

Required Storage Conditions

Condition Requirement
Temperature Store in a refrigerator between +2 C and +8 C (Do not freeze).
Protection Keep the product in the original outer carton to protect it from light.
Safety Keep out of the sight and reach of children.
Stability Must be used immediately after the container is opened.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. Medicines must not be discarded via wastewater or general household waste. Do not use the medicine past the expiration date on the package.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Berirab -P found in:

A-Z Index: